MSD has entered its final stage of developing combination drug 'Atozet'

MSD which was in the shadow of Pfizer and Astrazenaca in the domestic hyperlipidemia market, is seeking a reversal with composite hyperlipidemia treatment. MSD has entered its final stage of developing combination drug 'Atozet' which is composed of 'Atorvastatin' and cholesterol absorption inhibitor 'Ezetimibe'. MSD has already released 'Vytorin' which is composed of statin family drug 'Simvast...